Our results driven ethic and approach is what separates KCSA from other communications firms.
Looking to raise product and investor awareness around transition from Australian to U.S. markets
Unilife Corporation, a developer, manufacturer and supplier of advanced drug delivery systems, retained KCSA in 2010 to assist with its redomicile to the U.S. from Australia and subsequent listing on NASDAQ. Entering a new market, the Company needed assistance in implementing and conveying its growth strategy to the U.S. investment community as well as in putting into place an ongoing proactive communications program to support sales.
KCSA designed a detailed IR strategy that included roadshows, conferences and other investor related events. These efforts integrated with a public relations effort where the primary objective was to position Unilife as a game changing and comprehensive medical solutions provider. As part of the PR program, KCSA also implemented an all-inclusive social media strategy to expand Unilife's presence on Twitter, Facebook and YouTube to ensure that all targeted audiences including healthcare personnel, pharmaceutical company professionals and investors were made aware of the Company.
Since retaining KCSA, awareness of Unilife has significantly increased with respect to all of its constituents. On the investor relations front, U.S. based institutional investors now hold nearly 50% of the shares outstanding (as compared to hardly any when the company first came to the U.S.). The company has active research coverage from six sell-side analysts.
As a result of the PR and social media effort, Unilife has benefited from broad financial media coverage, including appearances on Mad Money, Fox Business and TheStreet.com TV, as well as being featured in many top-tier business and trade publications, including The Philadelphia Inquirer, Central Penn Business Journal, OnDrug Delivery, Medical Device and Diagnostic Industry Magazine. These activities have contributed to the Company’s increased profile in the pharmaceutical industry. As a result, the company has signed a number of commercial supply and development agreements with pharmaceutical companies around the world, including Sanofi, Hikma and MedImmune, the global biologics research and development arm of AstraZeneca.